References84. Kunkel TA (1993) Nucleotide repeats. Slippery DNA <strong>and</strong> diseases. Nature365(6443): 207-20885. Loeb LA, Monnat RJ, Jr. (2008) DNA polymerases <strong>and</strong> human disease. Nat RevGenet 9(8): 594-60486. Kunkel TA, Bebenek K (2000) DNA replication fidelity. Annu Rev Biochem69:497-529. 497-52987. Kuismanen SA, Holmberg MT, Salovaara R, de la CA, Peltomäki P (2000) Genetic<strong>and</strong> epi<strong>genetic</strong> modification of MLH1 accounts for a major share ofmicrosatellite-unstable colorectal cancers. Am J Pathol 156(5): 1773-177988. Duval A, Iacopetta B, Thorstensen L, Mel<strong>in</strong>g GI, Lothe RA, Thuille B, Suraweera N,Thomas G, Hamel<strong>in</strong> R (2001) Gender difference for mismatch repair deficiency<strong>in</strong> human colorectal cancer. Gastroenterology 121(4): 1026-102789. Kroutil LC, Register K, Bebenek K, Kunkel TA (1996) Exonucleolyticproofread<strong>in</strong>g dur<strong>in</strong>g replication of repetitive DNA. Biochemistry 35(3): 1046-105390. Røyrvik EC, Ahlquist T, Rognes T, Lothe RA (2007) Slip slid<strong>in</strong>' away: aduodecennial review of targeted genes <strong>in</strong> mismatch repair deficient colorectalcancer. Crit Rev Oncog 13(3): 229-25791. Shibata D, Pe<strong>in</strong>ado MA, Io<strong>no</strong>v Y, Malkhosyan S, Perucho M (1994) Ge<strong>no</strong>mic<strong>in</strong>stability <strong>in</strong> repeated sequences is an early somatic event <strong>in</strong> colorectaltumorigenesis that persists after transformation. Nat Genet 6(3): 273-28192. Issa JP (2004) CpG isl<strong>and</strong> methylator phe<strong>no</strong>type <strong>in</strong> cancer. Nat Rev Cancer4(12): 988-99393. Goel A, Ar<strong>no</strong>ld CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM,Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertag<strong>no</strong>lli MM, Bol<strong>and</strong> CR(2003) Characterization of sporadic colon cancer by patterns of ge<strong>no</strong>mic<strong>in</strong>stability. Cancer Res 63(7): 1608-161494. Shen L, Catala<strong>no</strong> PJ, Benson AB, III, O'Dwyer P, Hamilton SR, Issa JP (2007)Association between DNA methylation <strong>and</strong> shortened survival <strong>in</strong> patientswith advanced colorectal cancer treated with 5-fluorouracil basedchemotherapy. Cl<strong>in</strong> Cancer Res 13(20): 6093-609895. Teodoridis JM, Hardie C, Brown R (2008) CpG isl<strong>and</strong> methylator phe<strong>no</strong>type(CIMP) <strong>in</strong> cancer: causes <strong>and</strong> implications. Cancer Lett 268(2): 177-18696. van RM, Elsaleh H, Joseph D, McCaul K, Iacopetta B (2003) CpG isl<strong>and</strong>methylator phe<strong>no</strong>type is an <strong>in</strong>dependent predictor of survival benefit from 5-fluorouracil <strong>in</strong> stage III colorectal cancer. Cl<strong>in</strong> Cancer Res 9(8): 2898-290374
References97. Samowitz WS, Albertsen H, Herrick J, Lev<strong>in</strong> TR, Sweeney C, Murtaugh MA, WolffRK, Slattery ML (2005) Evaluation of a large, population-based samplesupports a CpG isl<strong>and</strong> methylator phe<strong>no</strong>type <strong>in</strong> colon cancer. Gastroenterology129(3): 837-84598. Shen L, Toyota M, Kondo Y, L<strong>in</strong> E, Zhang L, Guo Y, Hern<strong>and</strong>ez NS, Chen X,Ahmed S, Konishi K, Hamilton SR, Issa JP (2007) Integrated <strong>genetic</strong> <strong>and</strong>epi<strong>genetic</strong> analysis identifies three different subclasses of colon cancer. ProcNatl Acad Sci U S A 104(47): 18654-1865999. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H (2007)APC mutations <strong>and</strong> other <strong>genetic</strong> <strong>and</strong> epi<strong>genetic</strong> changes <strong>in</strong> colon cancer.Mol Cancer Res 5(2): 165-170100. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ (2004) BRAF <strong>and</strong> KRASMutations <strong>in</strong> hyperplastic polyps <strong>and</strong> serrated ade<strong>no</strong>mas of the colorectum:relationship to histology <strong>and</strong> CpG isl<strong>and</strong> methylation status. Am J Surg Pathol28(11): 1452-1459101. van RM, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation ofcolorectal cancers show<strong>in</strong>g hypermethylation at multiple CpG isl<strong>and</strong>s. Gut51(6): 797-802102. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, P<strong>and</strong>eya N, Young J,Meltzer SJ, Leggett BA, Jass JR (2002) Morphological <strong>and</strong> molecularheterogeneity with<strong>in</strong> <strong>no</strong>nmicrosatellite <strong>in</strong>stability-high colorectal cancer.Cancer Res 62(21): 6011-6014103. Anacleto C, Leopold<strong>in</strong>o AM, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O,Camargo AA, Simpson AJ, Pena SD (2005) Colorectal cancer "methylatorphe<strong>no</strong>type": fact or artifact? Neoplasia 7(4): 331-335104. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH (2004) Aberrant CpG isl<strong>and</strong>hypermethylation of multiple genes <strong>in</strong> colorectal neoplasia. Lab Invest 84(7):884-893105. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M (2003) Genetics supersedesepi<strong>genetic</strong>s <strong>in</strong> colon cancer phe<strong>no</strong>type. Cancer Cell 4(2): 121-131106. Issa JP, Shen L, Toyota M (2005) CIMP, at last. Gastroenterology 129(3): 1121-1124107. Goel A, Nagasaka T, Ar<strong>no</strong>ld CN, I<strong>no</strong>ue T, Hamilton C, Niedzwiecki D, Compton C,Mayer RJ, Goldberg R, Bertag<strong>no</strong>lli MM, Bol<strong>and</strong> CR (2007) The CpG isl<strong>and</strong>methylator phe<strong>no</strong>type <strong>and</strong> chromosomal <strong>in</strong>stability are <strong>in</strong>versely correlated <strong>in</strong>sporadic colorectal cancer. Gastroenterology 132(1): 127-138108. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, KangGH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M,75
- Page 1 and 2:
Novel genetic and epigenetic altera
- Page 3 and 4:
TABLE OF CONTENTSACKNOWLEDGEMENTS .
- Page 5 and 6:
ACKNOWLEDGEMENTSThe present work ha
- Page 7 and 8:
Prefacetechnology[3]. This new tech
- Page 10 and 11:
SummaryThe subgroup of carcinomas w
- Page 12 and 13:
Introduction“Epigenetic inheritan
- Page 14 and 15:
Introductionamino acid change it is
- Page 16 and 17:
Introductionmethylation during embr
- Page 18 and 19:
IntroductionDNA is most of the time
- Page 20 and 21:
IntroductionFigure 5. DNA methylati
- Page 22 and 23:
IntroductionFigure 6. Incidence rat
- Page 24 and 25: IntroductionFigure 8. Tumor staging
- Page 26 and 27: Introductioninasmuch as 80% of colo
- Page 28 and 29: IntroductionInstabilities involved
- Page 30 and 31: Introductionthere seems to be a fid
- Page 32 and 33: Introductionsevere alterations are
- Page 34 and 35: Introductionpopulation-wide screeni
- Page 36 and 37: IntroductionFigure 12. Present and
- Page 38 and 39: RESULTS IN BRIEFPaper Ia. “DNA hy
- Page 40 and 41: Results in Briefinstability, and se
- Page 42 and 43: Results in BriefUnivariate survival
- Page 44 and 45: Discussionseveral factors, and full
- Page 46 and 47: Discussionlow threshold, we increas
- Page 48 and 49: DiscussionIt may seem like unnecess
- Page 50 and 51: Discussionthan 96% DHPLC do not sta
- Page 52 and 53: DiscussionFigure 13. Mutation detec
- Page 54 and 55: DiscussionClinical impact of molecu
- Page 56 and 57: Discussionmarkers with a very high
- Page 58 and 59: Discussionchromosomes in metaphase[
- Page 60 and 61: DiscussionThese examples underline
- Page 62 and 63: Discussiongenes. One is based on mu
- Page 64 and 65: CONCLUSIONSWe have identified novel
- Page 66 and 67: Future PerspectivesMolecular risk a
- Page 68 and 69: REFERENCES1. Breasted J (1930) The
- Page 70 and 71: References29. Deng G, Chen A, Pong
- Page 72 and 73: References57. Al-Sukhni W, Aronson
- Page 76 and 77: ReferencesLeggett B, Levine J, Kim
- Page 78 and 79: References133. Lind GE, Thorstensen
- Page 80 and 81: References156. Meling GI, Lothe RA,
- Page 82 and 83: ReferencesT, Song X, Day RH, Sledzi
- Page 84 and 85: References196. Honda S, Haruta M, S
- Page 86 and 87: ORIGINAL ARTICLESAPPENDIXAppendix I
- Page 89 and 90: GASTROENTEROLOGY 2007;132:1631-1639
- Page 91: Paper IbGuro E Lind, Terje Ahlquist
- Page 94 and 95: Journal of Translational Medicine 2
- Page 96 and 97: Journal of Translational Medicine 2
- Page 98 and 99: Journal of Translational Medicine 2
- Page 100 and 101: Journal of Translational Medicine 2
- Page 102 and 103: Journal of Translational Medicine 2
- Page 105: Paper IITerje Ahlquist, Guro E Lind
- Page 108 and 109: BackgroundMost cases of colorectal
- Page 110 and 111: ADAMTS1 CDKN2A CRABP1 HOXA9 MAL MGM
- Page 112 and 113: pseudogene, leading to a high rate
- Page 114 and 115: strands. Proc Natl Acad Sci U S A 1
- Page 116 and 117: concomitant absence of transcript a
- Page 119 and 120: Volume 10 Number 7 July 2008 pp. 68
- Page 121 and 122: 682 RAS Signaling in Colorectal Car
- Page 123 and 124: 684 RAS Signaling in Colorectal Car
- Page 125 and 126:
686 RAS Signaling in Colorectal Car
- Page 127:
Table W2. Detailed Somatic Events o
- Page 131 and 132:
Identification of RCC2 as a prognos
- Page 133 and 134:
INTRODUCTIONMicrosatellite instabil
- Page 135 and 136:
unselected series of primary tumors
- Page 137 and 138:
specificity, i.e. that they only am
- Page 139 and 140:
On the assumption that DNA repair a
- Page 141 and 142:
In order to ensure that gene mutati
- Page 143 and 144:
Figure 2. Mutation frequency differ
- Page 145 and 146:
and TAF1B (0.50), ACVR2A and ASTE1
- Page 147 and 148:
Multivariate analysesA multivariate
- Page 149 and 150:
When comparing our findings of muta
- Page 151 and 152:
The test series included a low numb
- Page 153 and 154:
entering M-phase remains to be seen
- Page 155 and 156:
12. Duval A, Reperant M, Hamelin R
- Page 157 and 158:
34. Martineau-Thuillier S, Andreass
- Page 159:
AppendicesAppendix I:List of abbrev
- Page 163 and 164:
Critical Reviews TM in Oncogenesis,
- Page 165 and 166:
TARGET GENES OF MSI COLORECTAL CANC
- Page 167 and 168:
TARGET GENES OF MSI COLORECTAL CANC
- Page 169 and 170:
TARGET GENES OF MSI COLORECTAL CANC
- Page 171 and 172:
TARGET GENES OF MSI COLORECTAL CANC
- Page 173 and 174:
TARGET GENES OF MSI COLORECTAL CANC
- Page 175 and 176:
TARGET GENES OF MSI COLORECTAL CANC
- Page 177 and 178:
TARGET GENES OF MSI COLORECTAL CANC
- Page 179 and 180:
TARGET GENES OF MSI COLORECTAL CANC
- Page 181 and 182:
TARGET GENES OF MSI COLORECTAL CANC
- Page 183 and 184:
TARGET GENES OF MSI COLORECTAL CANC
- Page 185 and 186:
TARGET GENES OF MSI COLORECTAL CANC
- Page 187 and 188:
TARGET GENES OF MSI COLORECTAL CANC
- Page 189 and 190:
TARGET GENES OF MSI COLORECTAL CANC
- Page 191:
TARGET GENES OF MSI COLORECTAL CANC